Market Cap 356.87M
Revenue (ttm) 20,000.00
Net Income (ttm) -95.06M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -475,300.00%
Debt to Equity Ratio 0.00
Volume 4,156,600
Avg Vol 6,325,818
Day's Range N/A - N/A
Shares Out 81.11M
Stochastic %K 49%
Beta 0.47
Analysts Strong Sell
Price Target $22.38

Company Profile

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 trial for the treatment of obesity and metabolic associated steatohepatitis. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.

Industry: Biotechnology
Sector: Healthcare
Phone: 240 654 1450
Address:
910 Clopper Road, Suite 201S, Gaithersburg, United States
GreenEnergy2022
GreenEnergy2022 Jul. 12 at 7:48 AM
$ALT 24:50. Pfizer earnings report 5th August. Novartis next week! 07/17/2025 https://event.webcasts.com/viewer/event.jsp?ei=1721232&tp_key=564058e879
1 · Reply
bigbigwin
bigbigwin Jul. 12 at 5:28 AM
$ALT Nwbo, their cancer vaccine is waiting the approval in UK. Read the latest news in UK. 🤖🤖Not financial Advice https://x.com/Siobhain_Mc/status/1943693040436048228?t=RjeFgjbv62EnJAhk2HFAow&s=08
0 · Reply
bigbigwin
bigbigwin Jul. 12 at 5:23 AM
$ALT NWBO , take a look. They are waiting the approval in UK. Dcvax L is suitable not just glioblastoma and other 14 different solid cancers. Not financial Advice.
1 · Reply
danws
danws Jul. 12 at 5:05 AM
$ALT i am looking forward to earnings date too
0 · Reply
Turribull
Turribull Jul. 12 at 4:42 AM
$ALT Only 17 trading days until ER. 👀 Thank you for your attention to this matter!
0 · Reply
BioRich
BioRich Jul. 12 at 4:31 AM
$ALT @Jacked_Nicholson @Popeye989 While simple minds focus on the Sentiment button, sophisticated minds focus on content. I have shared explanations for every post I've made about $ALT over the past year and a half. 99% of them were negative. Recent Bullish posts were related to $ALT's potential for SP improvement from the unknown potentially positive effect of using AI data to support fibrosis improvement. Not resting on hopium, I researched further (as I've consistently done) and found that the AI hope was far less impressive as the company didn't present AI data for Fibrosis that would support their claims. Furthermore, additional analysis of presented data showed ALT failed their MASH P2b trial in the primary focus (fibrosis improvement) worse than the data they highlighted that still dropped SP 60%. So sure, I've posted positives and negatives. I've tabbed Bearish (mostly) and Bullish. I believe it's a sign of continued research and not stagnant hope. Cheers! $XBI $CAPR $IBB
1 · Reply
BioRich
BioRich Jul. 12 at 4:07 AM
$ALT @Jacked_Nicholson As many have mentioned, this is an excellent message you sent to $ALT. I hope that you hear a response. As a side note, not to detract from the excellent email, I believe $ALT management is silent because they know they are screwed. The Fibrosis Improvement failure is sort of a kill shot for them. They even tried to fluff the data and it still failed. In their MASH data, competitors are better and further along. In Obesity, they're not a player and have known that for a long time. Remember, they are great at going into silent mode when they are avoiding. They did that when they did their PR blitz (CNBC) and went radio silent for months while the stock tanked 40% and not a peep from management. Very frustrating. As a second side note, I don't believe that the AI tool $ALT used is approved for use in the US. Doesn't mean it won't, but currently it's not an approved method. Once it is (expected), it will be interesting to see how the FDA handles it.
0 · Reply
emerytitus
emerytitus Jul. 12 at 3:40 AM
$ALT @cryptobearcat Damn good to have you back boy
0 · Reply
BioRich
BioRich Jul. 12 at 3:39 AM
$ALT @dcrown Easy explanation, this wasn't from Goldman Sachs. References to $ALT by Goldman Sachs was from before ALT failed their MASH P2b data. The narrative was not from Goldman Sachs, rather someone else discussing Goldman Sachs picks (before they failed Fibrosis Improvement). Take a look at your source and the dates. The information included is NOT from Goldman Sachs. Thanks for asking because I wouldn't want people to go down the wrong path thinking Goldman Sachs pumped this before it dumped it. For fun, the article you reference conveniently omitted the Fibrosis Improvement failure. Hope this helps. Here's the article that you're misleadingly referencing: https://www.insidermonkey.com/blog/goldman-sachs-penny-stocks-top-12-stock-picks-2-1563813/
0 · Reply
BioRich
BioRich Jul. 12 at 3:08 AM
$ALT Goldman Sachs summarized it, I explained it. Any questions?
0 · Reply
Latest News on ALT
Altimmune's Fatty Liver Candidate Faces Differentiation Doubts

Jun 27, 2025, 2:39 PM EDT - 14 days ago

Altimmune's Fatty Liver Candidate Faces Differentiation Doubts


Altimmune: Deciphering The MASH Crash (Rating Upgrade)

Jun 26, 2025, 4:30 PM EDT - 15 days ago

Altimmune: Deciphering The MASH Crash (Rating Upgrade)


Altimmune to Participate at Two Upcoming Investor Conferences

May 14, 2025, 7:30 AM EDT - 2 months ago

Altimmune to Participate at Two Upcoming Investor Conferences


Altimmune, Inc. (ALT) Q1 2025 Earnings Call Transcript

May 13, 2025, 2:57 PM EDT - 2 months ago

Altimmune, Inc. (ALT) Q1 2025 Earnings Call Transcript


Altimmune to Host Virtual R&D Day on March 13, 2025

Mar 6, 2025, 7:30 AM EST - 4 months ago

Altimmune to Host Virtual R&D Day on March 13, 2025


Altimmune, Inc. (ALT) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 2:24 PM EST - 4 months ago

Altimmune, Inc. (ALT) Q4 2024 Earnings Call Transcript


Final Trade: WST, BTC, GLD, ALT

Feb 14, 2025, 6:32 PM EST - 5 months ago

Final Trade: WST, BTC, GLD, ALT

GLD BTC WST


Altimmune Could Find A Partner For Its Phase 3 Exercise

Dec 30, 2024, 11:42 AM EST - 6 months ago

Altimmune Could Find A Partner For Its Phase 3 Exercise


Altimmune Added to Nasdaq Biotechnology Index

Dec 19, 2024, 7:30 AM EST - 7 months ago

Altimmune Added to Nasdaq Biotechnology Index


Altimmune 2025: Redefining Obesity And MASH Treatment

Dec 16, 2024, 3:14 AM EST - 7 months ago

Altimmune 2025: Redefining Obesity And MASH Treatment


Altimmune CEO on what's next for its experimental obesity drug

Dec 3, 2024, 6:04 PM EST - 7 months ago

Altimmune CEO on what's next for its experimental obesity drug


Final Trade: C, NVDA, XLF, ALT

Nov 19, 2024, 6:29 PM EST - 8 months ago

Final Trade: C, NVDA, XLF, ALT

NVDA XLF C


Altimmune, Inc. (ALT) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 10:00 AM EST - 8 months ago

Altimmune, Inc. (ALT) Q3 2024 Earnings Call Transcript


Consider Buying Potential Takeover Target Altimmune

Oct 2, 2024, 2:48 PM EDT - 10 months ago

Consider Buying Potential Takeover Target Altimmune


GreenEnergy2022
GreenEnergy2022 Jul. 12 at 7:48 AM
$ALT 24:50. Pfizer earnings report 5th August. Novartis next week! 07/17/2025 https://event.webcasts.com/viewer/event.jsp?ei=1721232&tp_key=564058e879
1 · Reply
bigbigwin
bigbigwin Jul. 12 at 5:28 AM
$ALT Nwbo, their cancer vaccine is waiting the approval in UK. Read the latest news in UK. 🤖🤖Not financial Advice https://x.com/Siobhain_Mc/status/1943693040436048228?t=RjeFgjbv62EnJAhk2HFAow&s=08
0 · Reply
bigbigwin
bigbigwin Jul. 12 at 5:23 AM
$ALT NWBO , take a look. They are waiting the approval in UK. Dcvax L is suitable not just glioblastoma and other 14 different solid cancers. Not financial Advice.
1 · Reply
danws
danws Jul. 12 at 5:05 AM
$ALT i am looking forward to earnings date too
0 · Reply
Turribull
Turribull Jul. 12 at 4:42 AM
$ALT Only 17 trading days until ER. 👀 Thank you for your attention to this matter!
0 · Reply
BioRich
BioRich Jul. 12 at 4:31 AM
$ALT @Jacked_Nicholson @Popeye989 While simple minds focus on the Sentiment button, sophisticated minds focus on content. I have shared explanations for every post I've made about $ALT over the past year and a half. 99% of them were negative. Recent Bullish posts were related to $ALT's potential for SP improvement from the unknown potentially positive effect of using AI data to support fibrosis improvement. Not resting on hopium, I researched further (as I've consistently done) and found that the AI hope was far less impressive as the company didn't present AI data for Fibrosis that would support their claims. Furthermore, additional analysis of presented data showed ALT failed their MASH P2b trial in the primary focus (fibrosis improvement) worse than the data they highlighted that still dropped SP 60%. So sure, I've posted positives and negatives. I've tabbed Bearish (mostly) and Bullish. I believe it's a sign of continued research and not stagnant hope. Cheers! $XBI $CAPR $IBB
1 · Reply
BioRich
BioRich Jul. 12 at 4:07 AM
$ALT @Jacked_Nicholson As many have mentioned, this is an excellent message you sent to $ALT. I hope that you hear a response. As a side note, not to detract from the excellent email, I believe $ALT management is silent because they know they are screwed. The Fibrosis Improvement failure is sort of a kill shot for them. They even tried to fluff the data and it still failed. In their MASH data, competitors are better and further along. In Obesity, they're not a player and have known that for a long time. Remember, they are great at going into silent mode when they are avoiding. They did that when they did their PR blitz (CNBC) and went radio silent for months while the stock tanked 40% and not a peep from management. Very frustrating. As a second side note, I don't believe that the AI tool $ALT used is approved for use in the US. Doesn't mean it won't, but currently it's not an approved method. Once it is (expected), it will be interesting to see how the FDA handles it.
0 · Reply
emerytitus
emerytitus Jul. 12 at 3:40 AM
$ALT @cryptobearcat Damn good to have you back boy
0 · Reply
BioRich
BioRich Jul. 12 at 3:39 AM
$ALT @dcrown Easy explanation, this wasn't from Goldman Sachs. References to $ALT by Goldman Sachs was from before ALT failed their MASH P2b data. The narrative was not from Goldman Sachs, rather someone else discussing Goldman Sachs picks (before they failed Fibrosis Improvement). Take a look at your source and the dates. The information included is NOT from Goldman Sachs. Thanks for asking because I wouldn't want people to go down the wrong path thinking Goldman Sachs pumped this before it dumped it. For fun, the article you reference conveniently omitted the Fibrosis Improvement failure. Hope this helps. Here's the article that you're misleadingly referencing: https://www.insidermonkey.com/blog/goldman-sachs-penny-stocks-top-12-stock-picks-2-1563813/
0 · Reply
BioRich
BioRich Jul. 12 at 3:08 AM
$ALT Goldman Sachs summarized it, I explained it. Any questions?
0 · Reply
jacksparo
jacksparo Jul. 12 at 2:06 AM
$ALT I am working on a new update and a new plan to share via the email this weekend after a big fight against this short this week. ALT closed above four this week! $AKBA A steady chart and a steady good close now; all eyes are on the incoming earnings season here! $GNS One of the most volatile weeks in GNS since 2022. We're far away from the fun, and I'm making some new plans to share soon with both my email and Telegram groups! $GEVO Another swing zone is getting closer here; I have some more updates about this one to be shared soon! Enjoy your Friday night, team members and followers!
0 · Reply
Cryptobearcat
Cryptobearcat Jul. 12 at 2:06 AM
$ALT i lied this is the last post! Confucious say……… https://www.instagram.com/reel/DL3kfKJPdAP/?igsh=aTl3cGRjNTZxMXg4
1 · Reply
Jacked_Nicholson
Jacked_Nicholson Jul. 12 at 1:57 AM
$ALT Possibly a stupid question, but if they have the 48 week data in August and they don’t have to read biopsies, why would they wait until Q4 to share the data? Wishful thinking… are they keeping a buffer for negotiations with suitors under NDA?
3 · Reply
Cryptobearcat
Cryptobearcat Jul. 12 at 1:52 AM
$ALT last rage post of the night, then gotta go do my husbandly duties to my beautiful wife LOLOL For all y'all that worry about current share price and reconciling in your head, how the hell can it get to a buy out of say $100/ share or more. Cuz when you google buyouts it always say so and so company bought for 120% premium etc etc. Google does not lie often LOL, but frequently it does not tell the full story. Those share prices typically make massive jumps in the wks, months leading up the final deal consummation due to rumors or announcements. Take a look at VKTX, my fav whipping boy, which I actually invested in. I had a small position, in at ~$9, then there was rumor of imminent buyout, it jumped in a few wks to over $90 intraday, by then I was long out. But let's say the buyout was true. Ppl were talking about 12-15 billion at the time. Then it would have been 1.2 to 1.4x the $90 share price it was trading at before coming back down! So if you want a GPS road map. That is how!
3 · Reply
Jacked_Nicholson
Jacked_Nicholson Jul. 12 at 1:45 AM
$ALT Do you guys remember this one? https://tekinvestor.s3.dualstack.eu-west-1.amazonaws.com/original/3X/d/e/defca2bfb965feeeb0a7cbc0eb69962948d01bed.pdf
2 · Reply
Cryptobearcat
Cryptobearcat Jul. 12 at 1:31 AM
$ALT There are ~ 1000 Hepatologists in USA. Eventually all the people who suffer from NAFLD (non alcoholic fatty liver disease) 80-100 million, NASH 9-15 million, ALD 10-17 million all have to see these 1000 MD/DOs at least once for consultation and treatment. Before Resmetirom there were no medical treatment for NASH. Yet, only a tiny 15 some thousand by my calculation using MDGL's 2024 profit and monthly cost of Resmetirom. Why? is it these 1000 MDs are really lazy and poorly informed, don't talk to their colleagues, don't attend conferences, don't read journals and just piss poor doctors? I think not, I think Resmetirom is just not that good. Which is why FDA still gave fast track designation to Pemvi. Once approved, all the owner of Pemvi needs to do is educate and market to 1000 doctors. And sit back and watch the money flows in!
1 · Reply
All_just_a_game
All_just_a_game Jul. 12 at 1:28 AM
$ALT Q2 earnings on tap…let’s see how many shares were sold through the ATM while waiting for this best in class data.
1 · Reply
Cryptobearcat
Cryptobearcat Jul. 12 at 1:06 AM
$ALT Guys, I been away for 12 days, and every old longs here have turned into PUSSIES, WTF! Oh happy with $55/share, oh 3-4 Billion. Ok, let me do an intervention for y'all. Here are the things Pemvi does that NO OTHER DRUGS legal or illegal can do! 1) Shift metabolism from glucose bias to fat bias. 2) Lose weight yet have less lean muscle loss than diet & exercise alone. 3) Lower significantly small particle LDL (the major cause of stroke and heart attack), yes, no current cholesterol drugs can do that! 4) Treat ALD (alcohol liver disease), currently all medications listed by google are only treating symptoms not the cause. 5) Preferentially target deep visceral fat while saving SQ fat which is what makes you look young. 6) Directly lower 6 species of cardio inflammatory particles and nearly 100 subspecies of above. 17.8million ALD patients in USA. At Resmetirom price 2k/mo = 24k/yr. If only 5 mil gets treated before patent expires. That is 120Billion! This is just ALD! Say 3B again?
HarryScrotmsRashy
HarryScrotmsRashy Jul. 12 at 1:06 AM
$ALT I know you can't post on X is there somewhere you can post that could get viewed by them other than X or emailing them which they may or may not get ?
1 · Reply
SoldierOfFortune1985
SoldierOfFortune1985 Jul. 12 at 1:00 AM
$ALT KEEP YA HEAD UP BULLS! ONLY 166 DAYS FOR CHRISTMAS PRESENTS!!
0 · Reply
sanstock6262
sanstock6262 Jul. 12 at 12:54 AM
$ALT @grassosteve I know you have been a shareholder of $ALT -many of the retail investors have sent emails to ALT management about their silence and having no respect for their shareholders - maybe you can help us as well - i sent this to Steve Grasso as well maybe he can help
1 · Reply
WISH_upon_a_PLTR
WISH_upon_a_PLTR Jul. 12 at 12:40 AM
$ALT @Cryptobearcat What do you think of this Dr’s opinion? https://x.com/cigs1234/status/1943831709947957570?s=46&t=3N-CAwJDkLKz-QMh-IM6CQ
5 · Reply